| Autor: |
Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Hayri Bostan, Erman Çakal |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Turkish Journal of Internal Medicine, Vol 3, Iss Supplement 1, Pp 85-86 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2687-4245 |
| DOI: |
10.46310/tjim.877156 |
| Popis: |
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
